163 related articles for article (PubMed ID: 11376565)
1. CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNA in mouse liver.
Shimizu M; Tamura T; Yamada Y; Akiyama Y; Saijo N; Nishio K
Jpn J Cancer Res; 2001 May; 92(5):554-61. PubMed ID: 11376565
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.
Milano G; Chamorey AL
Chronobiol Int; 2002 Jan; 19(1):177-89. PubMed ID: 11962674
[TBL] [Abstract][Full Text] [Related]
3. Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression.
Porsin B; Formento JL; Filipski E; Etienne MC; Francoual M; Renée N; Magné N; Lévi F; Milano G
Eur J Cancer; 2003 Apr; 39(6):822-8. PubMed ID: 12651209
[TBL] [Abstract][Full Text] [Related]
4. Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls.
Raida M; Kliche KO; Schwabe W; Häusler P; Clement JH; Behnke D; Höffken K
J Cancer Res Clin Oncol; 2002 Feb; 128(2):96-102. PubMed ID: 11862480
[TBL] [Abstract][Full Text] [Related]
5. Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.
Cai X; Tian C; Wang L; Zhuang R; Zhang X; Guo Y; Lu H; Wang H; Li X; Gao J; Li Q; Wang C
Cancer Biol Ther; 2017 Mar; 18(3):186-193. PubMed ID: 28278081
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Smorenburg CH; Peters GJ; van Groeningen CJ; Noordhuis P; Smid K; van Riel AM; Dercksen W; Pinedo HM; Giaccone G
Ann Oncol; 2006 Jan; 17(1):35-42. PubMed ID: 16251201
[TBL] [Abstract][Full Text] [Related]
7. Regulation of dihydropyrimidine dehydrogenase gene expression in regenerating mouse liver.
Yamada H; Fukushima M; Koizumi K; Katakura H; Nakanishi H; Teshima S; Kamiyama Y; Ikenaka K
Int J Oncol; 2003 Feb; 22(2):359-64. PubMed ID: 12527935
[TBL] [Abstract][Full Text] [Related]
8. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice.
Ishikawa Y; Kubota T; Otani Y; Watanabe M; Teramoto T; Kumai K; Kitajima M; Takechi T; Okabe H; Fukushima M
Clin Cancer Res; 1999 Apr; 5(4):883-9. PubMed ID: 10213225
[TBL] [Abstract][Full Text] [Related]
9. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion.
Harris BE; Song R; Soong SJ; Diasio RB
Cancer Res; 1990 Jan; 50(1):197-201. PubMed ID: 2293556
[TBL] [Abstract][Full Text] [Related]
10. Circadian expression of dihydropyrimidine dehydrogenase, thymidylate synthase, c-myc and p53 mRNA in mouse liver tissue.
Wu MW; Xian LJ; Li XM; Pasquale I; Francis L
Ai Zheng; 2004 Mar; 23(3):235-42. PubMed ID: 15025949
[TBL] [Abstract][Full Text] [Related]
11. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy.
Zhang R; Lu Z; Liu T; Soong SJ; Diasio RB
Cancer Res; 1993 Jun; 53(12):2816-22. PubMed ID: 8504424
[TBL] [Abstract][Full Text] [Related]
12. Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil.
Kobuchi S; Hayashi A; Taniguchi M; Ito Y; Tamura T; Sakaeda T
Cancer Chemother Pharmacol; 2016 Sep; 78(3):517-23. PubMed ID: 27417318
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
14. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
Milano G; McLeod HL
Eur J Cancer; 2000 Jan; 36(1):37-42. PubMed ID: 10741292
[TBL] [Abstract][Full Text] [Related]
15. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.
Jiang H; Lu J; Ji J
Br J Pharmacol; 2004 Feb; 141(4):616-23. PubMed ID: 14744810
[TBL] [Abstract][Full Text] [Related]
16. 5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer.
Inada T; Ogata Y; Kubota T; Tomikawa M; Yamamoto S; Andoh J; Ozawa I; Hishinuma S; Shimizu H; Kotake K
Anticancer Res; 2000; 20(4):2457-62. PubMed ID: 10953310
[TBL] [Abstract][Full Text] [Related]
17. [Dihydropyrimidine deshydrogenase (DPD): rhythm and consequences].
Barrat-Petit MA; Naulin-Ifi C; Mahler P; Milano G
Pathol Biol (Paris); 2005 Jun; 53(5):261-4. PubMed ID: 15939134
[TBL] [Abstract][Full Text] [Related]
18. Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion.
Uchida K; Hayashi K; Kuramochi H; Takasaki K
Int J Oncol; 2001 Aug; 19(2):341-6. PubMed ID: 11445849
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer.
Ide H; Kikuchi E; Hasegawa M; Hattori S; Yasumizu Y; Miyajima A; Oya M
Cancer Med; 2013 Aug; 2(4):488-95. PubMed ID: 24156021
[TBL] [Abstract][Full Text] [Related]
20. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits.
Milano G; Etienne MC
Ther Drug Monit; 1996 Aug; 18(4):335-40. PubMed ID: 8857547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
